- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ABVC BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 11.12.24 | ABVC BioPharma gets $200K in cash from OncoX BioPharma | 1 | Seeking Alpha | ||
| 11.12.24 | ABVC BioPharma, Inc.: ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners | 2 | GlobeNewswire (USA) | ||
| 14.11.24 | ABVC BioPharma GAAP EPS of -$0.02, revenue of $0.38M | 1 | Seeking Alpha | ||
| 14.11.24 | ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones | 92 | GlobeNewswire (Europe) | ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could... ► Artikel lesen | |
| 14.11.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.24 | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 22.10.24 | ABVC BioPharma sichert sich zusätzliche Lizenzgebühren | 3 | Investing.com Deutsch | ||
| 22.10.24 | ABVC BioPharma, Inc.: ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners | 65 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous... ► Artikel lesen | |
| 22.10.24 | ABVC BioPharma secures additional licensing fees | 1 | Investing.com | ||
| 19.10.24 | ABVC BioPharma switches to new independent accounting firm | 1 | Investing.com | ||
| 19.10.24 | ABVC BioPharma wechselt zu neuer unabhängiger Wirtschaftsprüfungsgesellschaft | 1 | Investing.com Deutsch | ||
| 18.10.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.09.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.08.24 | ABVC BioPharma GAAP EPS of -$0.09 | 1 | Seeking Alpha | ||
| 15.08.24 | ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements | 164 | GlobeNewswire (Europe) | • Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained... ► Artikel lesen | |
| 15.08.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08.24 | ABVC BIOPHARMA, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 23.07.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.07.24 | ABVC BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,395 | -0,36 % | NanoRepro Aktie: Alles im Blick? | Die NanoRepro AG, ein führender Entwickler medizinischer Selbsttests, zeigt sich trotz wirtschaftlicher Herausforderungen widerstandsfähig. Am 09. November 2024 notierte die Aktie bei 1,64 EUR, unverändert... ► Artikel lesen | |
| BIOXXMED | 1,190 | -4,03 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Strategiewechsel und Kostenreduktion | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Strategiewechsel und Kostenreduktion
28.11.2024 / 11:51 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,036 | -8,86 % | Sirona Biochem Aktie: Starkes Zeichen für die Zukunft | Die kanadische Biotechnologiefirma Sirona Biochem verzeichnet eine bemerkenswerte Kursentwicklung im November 2024. Mit einem aktuellen Kurs von 0,05075 EUR konnte das Unternehmen innerhalb des letzten... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,140 | 0,00 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,400 | +5,65 % | BioXcel Therapeutics Aktie: Ein Wendepunkt ins Negative? | Die BioXcel Therapeutics Aktie verzeichnet zum Ende des Monats November 2024 eine bemerkenswerte Schwächephase. Der aktuelle Kurs von 0,39 EUR spiegelt einen signifikanten monatlichen Rückgang von 31... ► Artikel lesen | |
| CELLECTIS | 1,472 | +0,68 % | Cellectis-Aktie stürzt auf 52-Wochen-Tief von 1,52 US-Dollar | ||
| SPERO THERAPEUTICS | 1,000 | +2,35 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,260 | 0,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth | Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,004 | 0,00 % | ALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| ADICET BIO | 0,859 | -3,27 % | Adicet Bio Appoints Julie Maltzman As CMO | WASHINGTON (dpa-AFX) - Adicet Bio, Inc. (ACET), a company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, said on Wednesday that it has appointed Julie... ► Artikel lesen | |
| DURECT | 0,890 | -1,11 % | DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update | - Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation
- Webcast of Earnings Call... ► Artikel lesen | |
| ALTAMIRA THERAPEUTICS | 0,300 | 0,00 % | Altamira Therapeutics Ltd: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA | ||
| WINDTREE THERAPEUTICS | 0,340 | 0,00 % | Windtree Therapeutics: Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia | WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative... ► Artikel lesen | |
| SERES THERAPEUTICS | 0,899 | -1,77 % | Seres Therapeutics, Inc.: FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) | Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy meeting... ► Artikel lesen |
Das Unternehmen ABVC BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,605 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABVC BIOPHARMA INC finden Sie auf Wallstreet Online.
